ProteoValent Therapeutics

Amphista Therapeutics

This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.

Biotheryx

The company develops protein degrader medicines for patients with cancer and inflammatory diseases.

Plexium

This company develops targeted protein degradation therapeutics and discovery platforms for patients with cancer and neurodegenerative diseases.

Enodia

This company develops small-molecule therapies that degrade disease-causing proteins at the point of synthesis for patients with cancer and inflammatory diseases.

Ligature Therapeutics

This biotech company develops protein degrader therapeutics using a fragment-based discovery platform to treat intractable diseases for patients with cancer.

Sibylla Biotech

This company develops small molecule protein degraders for pharmaceutical partners and clinical research to treat oncological and neurodegenerative diseases.

Nurix Therapeutics

This company develops targeted protein degradation therapies to treat patients with cancer and autoimmune diseases.

UPPTHERA

The company develops targeted protein degradation therapies for patients with cancer and rare diseases and provides platform technologies to pharmaceutical and biotechnology companies.